Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Kanglin Biotechnology

Request full access

Develops innovative gene therapies for serious diseases like AIDS, Parkinson's, hemophilia, and thalassemia

Hangzhou, ChinaFounded 2015Biotech & Life Sciences

About Kanglin Biotechnology

Kanglin Biotechnology (Hangzhou) Co., Ltd., founded in 2015, is a clinical-stage biopharmaceutical company focused on developing and commercializing gene therapies. The company was established by Dr. Haoquan Wu, who serves as the CEO. Dr. Wu has an extensive academic and research background, holding a Ph.D. from Fudan University, followed by postdoctoral positions at UCLA and Harvard University, and faculty positions at Texas Tech University before dedicating himself full-time to Kanglin Biotechnology.

The company's primary objective is to create first-in-class and best-in-class gene therapy drugs to address severe diseases with significant unmet medical needs. Its therapeutic pipeline targets conditions such as beta thalassemia, sickle cell disease, AIDS, Parkinson's disease, and hemophilia. Kanglin Biotechnology operates in the advanced therapies market, developing treatments that have the potential to offer one-time curative interventions for patients.

The firm's lead product candidate, KL003, is a lentiviral vector gene therapy designed for the treatment of transfusion-dependent beta thalassemia and sickle cell disease. This therapy works by delivering a functional ß-globin gene in a single treatment. Clinical trials have shown promising results, with a Phase 1 study demonstrating 100% efficacy in 17 patients, leading to faster transfusion independence and engraftment compared to other gene therapies. KL003 has received both Orphan Drug Designation (ODD) and Pediatric Rare Disease Designation (PRDD) from the U.S. Food and Drug Administration (FDA), and its clinical trial application was approved by China's Center for Drug Evaluation (CDE) in January 2024. A key differentiator for KL003 is its significantly reduced manufacturing cost compared to currently available gene therapies, which could improve patient access to the treatment.

Kanglin Biotechnology's business model is centered on the research, development, and eventual commercialization of its proprietary gene therapies. The company has secured significant funding to advance its clinical pipeline, including a $20 million Series A round to support the development of KL003 and other pipeline candidates. The company has established a GMP-compliant cell production line to meet both clinical and future commercial manufacturing demands. It actively seeks strategic partnerships for clinical research in areas including infectious diseases, neurodegenerative diseases, monogenic hereditary diseases, and ophthalmology.

Source: Dealroom company data

At a glance

Status
Operational
Employees
16
Open positions
None listed
Dealroom signal
24.0/100
Industry
Health
Sub-industry
Pharmaceutical, BioTechnology
Sector
Biotechnology, Gene Therapy, Spinout, Biotech and Pharma, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B

Funding history

2 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES A✓Equity / VC Nov 2024 $20M $80M Undisclosed ↗
SPINOUT✓Other financing Jan 2015 $0 — Texas Tech University —
Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Growth signals

Kanglin Biotechnology website traffic

Latest recorded traffic for Kanglin Biotechnology is 1.6K monthly website visits, up 110.5% over the last three months.

Latest monthly visits1.6K 3-month web change+110.5%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Kanglin Biotechnology in the Hangzhou ecosystem

Live from Dealroom

The Kanglin Biotechnology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

1 investor on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Other known investors1 additional known investor

  • Texas Tech University
Employees 16 total headcount
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇨🇳 China100%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Kanglin Biotechnology on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Kanglin Biotechnology’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.